BlackRock, Inc. filed an amended beneficial ownership statement with the SEC on October 27, 2026, reporting a holdings position in Roivant Sciences Ltd as of the event date of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock, Inc. reported beneficial ownership of 59,285,183 shares of Roivant Sciences Ltd common stock.
  • Percent of class: The reported position represents 8.2% of the outstanding common shares of Roivant Sciences Ltd.
  • Sole voting power: BlackRock disclosed sole voting power over 56,524,198 shares, with shared voting power of 0.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 59,285,183 shares, with shared dispositive power of 0.
  • Event date: The event requiring the filing occurred on September 30, 2026.
  • Filer type: BlackRock is identified as a parent holding company or control person, organized in Delaware, headquartered at 50 Hudson Yards, New York, NY 10001.

BlackRock's Reported Position in Roivant Sciences Common Stock

According to the filing, BlackRock, Inc. submitted Amendment No. 1 to its beneficial ownership statement covering common stock of Roivant Sciences Ltd, a biopharmaceutical holding company whose principal executive offices are located at 7th Floor, 50 Broadway, London, United Kingdom SW1H 0DB. The filing reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, referred to in the filing as the "Reporting Business Units."

The filing states that the aggregate amount beneficially owned by BlackRock as of September 30, 2026, was 59,285,183 shares, equal to 8.2% of the class. BlackRock disclosed sole voting power over 56,524,198 of those shares, while sole dispositive power covers the full 59,285,183 shares. Both shared voting power and shared dispositive power are reported as 0. The filing notes that the disclosure does not include securities, if any, beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units, in accordance with SEC Release No. 34-39538 (January 12, 1998).

Regarding dividends and proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ROIVANT SCIENCES LTD," and further that "no one person's interest in the common stock of ROIVANT SCIENCES LTD is more than five percent of the total outstanding common shares." The statement was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026. Subsidiary identification details are referenced in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. disclosed beneficial ownership of 59,285,183 shares, or 8.2%, of Roivant Sciences Ltd common stock (CUSIP G76279101) as of September 30, 2026, in an amended filing signed October 27, 2026, by Managing Director Spencer Fleming.